Collaboration will provide Illumigen with IB657 to enter Phase1a trials.

Avecia and Illumigen Biosciences entered into an agreement for the process development and manufacture of Illumigen’s lead development product, IB657, for the treatment of Hepatitis C and other RNA viruses.


Avecia will carry out development work to optimize the drug manufacturing process and conduct initial cGMP manufacture of IB657. This manufacturing agreement will provide Illumigen with IB657 in sufficient quantities to complete Phase Ia trials in Hepatitis C-infected patients.

Previous articleBiomira Gains Oncology Therapeutics through Purchase of ProlX
Next articleAvantogen’s IND for Pancreatic Cancer Drug Candidate Given Consent